company background image
INFI.Q logo

Infinity Pharmaceuticals OTCPK:INFI.Q Stock Report

Last Price

US$0.000001

Market Cap

US$90.0

7D

0%

1Y

-100.0%

Updated

11 Mar, 2024

Data

Company Financials

Infinity Pharmaceuticals, Inc.

OTCPK:INFI.Q Stock Report

Market Cap: US$90.0

INFI.Q Stock Overview

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer.

INFI.Q fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Infinity Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Infinity Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.000001
52 Week HighUS$0.26
52 Week LowUS$0.000001
Beta1.33
1 Month Change-99.00%
3 Month Change-99.96%
1 Year Change-100.00%
3 Year Change-100.00%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Nov 10
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Infinity Pharmaceuticals: Waiting For A Deal

Sep 08

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

May 23
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Dec 29
We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Investigating Infinity Pharmaceuticals

Nov 25

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Jul 18
Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Jun 03
Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Apr 13
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Feb 19
Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Jan 15
Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer

Jan 06

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Dec 11
Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium

Dec 09

Infinity Pharmaceutical Reaching Vital New Staging Posts

Dec 01

Shareholder Returns

INFI.QUS BiotechsUS Market
7D0%0.9%0.4%
1Y-100.0%10.3%28.8%

Return vs Industry: INFI.Q underperformed the US Biotechs industry which returned 16% over the past year.

Return vs Market: INFI.Q underperformed the US Market which returned 31% over the past year.

Price Volatility

Is INFI.Q's price volatile compared to industry and market?
INFI.Q volatility
INFI.Q Average Weekly Movement188.6%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: INFI.Q's share price has been volatile over the past 3 months.

Volatility Over Time: INFI.Q's weekly volatility has increased from 89% to 189% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199530Seth Taskerhttps://www.infi.com

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company’s product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

Infinity Pharmaceuticals, Inc. Fundamentals Summary

How do Infinity Pharmaceuticals's earnings and revenue compare to its market cap?
INFI.Q fundamental statistics
Market capUS$90.00
Earnings (TTM)-US$40.95m
Revenue (TTM)US$2.57m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INFI.Q income statement (TTM)
RevenueUS$2.57m
Cost of RevenueUS$28.53m
Gross Profit-US$25.96m
Other ExpensesUS$14.99m
Earnings-US$40.95m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.45
Gross Margin-1,010.35%
Net Profit Margin-1,593.93%
Debt/Equity Ratio-127.9%

How did INFI.Q perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.